Patent · US Active

Use of proteolysis resistant active VEGF

US8168590B2 · kind B2 · utility

0Cited by

2References

18Claims

0Family size

Assignee

BAYER INNOVATION GMBH · DE

Inventors

Sabine Eming · Cologne, DE
Thomas Krieg · Erbach, DE
Stephan Sollberg · Schwerin, DE
Gereon Lauer · Radolfzell, DE

Key dates

Filing date	Jan 7, 2009
Grant date	May 1, 2012
Priority date	—
Expiry date	Nov 2, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to vascular endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.